Raven Biotechnologies Overview

  • Founded
  • 1999

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $25M

Raven Biotechnologies General Information

Description

Developer of monoclonal antibody therapeutics created to treat cancer. The company's lead product candidate, RAV12, targets adenocarcinomas and simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them, identifying novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane for the treatment of gastrointestinal and other cancers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 1140 Veterans Boulevard
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Raven Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 17-Jul-2008 $25M 00000 0000 Completed Generating Revenue/Not Profitable
9. Merger/Acquisition 01-Mar-2008 Cancelled Clinical Trials - General
8. Convertible Debt 12-Nov-2007 00.00 00000 Completed Generating Revenue/Not Profitable
7. Later Stage VC (Series D) 12-Oct-2005 000.00 00000 Completed Clinical Trials - General
6. Later Stage VC 28-Oct-2004 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 13-Mar-2003 000.00 00000 Completed Pre-Clinical Trials
4. Later Stage VC (Series C) 02-Jan-2003 000.00 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 08-Jan-2001 000.00 000.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2000 Completed Pre-Clinical Trials
To view Raven Biotechnologies’s complete valuation and funding history, request access »

Raven Biotechnologies Patents

Raven Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080206819-A1 Growing cells in a perfusion system using induction agents without a substantial loss of cell viability; agent is sodium butyrate Inactive 21-Aug-2006 0000000000
US-20080124329-A1 Using combinations of antitumor agents and chimeric immunoglobulins as tool in treatment and prevention of infectious, cell proliferative, autoimmune, nervous system, cardiovascular and inflamatory disorders Inactive 05-Jul-2006 000000000
US-20100028344-A1 Conditioned cell immunization Inactive 05-Jul-2006 000000000
CA-2597198-A1 Antibodies that bind to epha2 and methods of use thereof Active 04-Feb-2005 000000000
EP-1846450-A2 Antibodies that bind to epha2 and methods of use thereof Active 04-Feb-2005 C07K16/30
To view Raven Biotechnologies’s complete patent history, request access »

Raven Biotechnologies Former Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bear Stearns Health InnoVentures Management Venture Capital Minority 000 0000 000000 0
CIDC Consultants Venture Capital Minority 000 0000 000000 0
Cercano Management Venture Capital Minority 000 0000 000000 0
China Investment & Development Venture Capital Minority 000 0000 000000 0
Cogene Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »